Sight Sciences [SGHT] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Sight Sciences Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Sight Sciences Inc. wins in 3 metrics, Abbott Laboratories wins in 14 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Sight Sciences Inc. Abbott Laboratories Better
P/E Ratio (TTM) N/A 25.97 N/A
Price-to-Book Ratio 3.66 3.09 Abbott Laboratories
Debt-to-Equity Ratio 63.77 26.79 Abbott Laboratories
PEG Ratio -7.85 -1.41 Abbott Laboratories
EV/EBITDA -5.39 13.74 Abbott Laboratories
Profit Margin (TTM) -49.67% 13.90% Abbott Laboratories
Operating Margin (TTM) -18.00% 16.50% Abbott Laboratories
EBITDA Margin (TTM) N/A 16.50% N/A
Return on Equity -50.74% 12.36% Abbott Laboratories
Return on Assets (TTM) -16.61% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $-29.92M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return 31.71% -35.92% Sight Sciences Inc.
Price-to-Sales Ratio (TTM) 3.07 3.57 Sight Sciences Inc.
Enterprise Value $182.12M $166.96B Abbott Laboratories
EV/Revenue Ratio 2.35 3.70 Sight Sciences Inc.
Gross Profit Margin (TTM) 87.26% N/A N/A
Revenue per Share (TTM) $1 $26 Abbott Laboratories
Earnings per Share (Diluted) $-0.74 $3.57 Abbott Laboratories
Beta (Stock Volatility) 2.49 0.78 Abbott Laboratories
Short % of Float 2.70% 1.53% Abbott Laboratories

Sight Sciences Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

SGHT
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sight Sciences Inc.0.00%-10.88%2.84%-17.49%-49.30%-41.98%
Abbott Laboratories0.02%1.53%-0.63%-23.43%-30.57%-29.95%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sight Sciences Inc.31.71%-35.37%-85.14%-85.14%-85.14%-85.14%
Abbott Laboratories-35.92%-17.85%-21.68%118.48%249.25%313.73%

Performance & Financial Health Analysis: Sight Sciences Inc. vs Abbott Laboratories

MetricSGHTABT
Market Information
Market Cap i$237.20M$160.70B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i460,06513,495,583
90 Day Avg. Volume i341,58512,934,461
Last Close$4.34$86.99
52 Week Range$3.11 - $9.24$81.97 - $139.06
% from 52W High-53.01%-37.44%
All-Time High$42.57 (Aug 02, 2021)$142.60 (Dec 27, 2021)
% from All-Time High-89.81%-39.00%
Growth Metrics
Quarterly Revenue Growth0.07%0.08%
Quarterly Earnings Growth0.07%-0.19%
Financial Health
Profit Margin (TTM) i-0.50%0.14%
Operating Margin (TTM) i-0.18%0.17%
Return on Equity (TTM) i-0.51%0.12%
Debt to Equity (MRQ) i63.7726.79
Cash & Liquidity
Book Value per Share (MRQ)$1.20$30.02
Cash per Share (MRQ)$1.70$5.14
Operating Cash Flow (TTM) i$-29,694,000$10.80B
Levered Free Cash Flow (TTM) i$-16,124,625$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Sight Sciences Inc. vs Abbott Laboratories

MetricSGHT (Apr 26, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A25.97
Forward P/E i-7.8515.29
PEG Ratio i-7.85-1.41
Price to Sales (TTM) i3.073.57
Price to Book (MRQ) i3.663.09
Market Capitalization
Market Capitalization i$237.20M$160.70B
Enterprise Value i$182.12M$166.96B
Enterprise Value Metrics
Enterprise to Revenue i2.353.70
Enterprise to EBITDA i-5.3913.74
Risk & Other Metrics
Beta i2.490.78
Book Value per Share (MRQ) i$1.20$30.02

Financial Statements Comparison: Sight Sciences Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSGHT (2025)ABT (2025)
Revenue/Sales i77.36M44.33B
Cost of Goods Sold i10.70M19.32B
COGS % of Revenue i13.8%43.6%
Gross Profit i66.67M25.01B
Gross Margin i86.2%56.4%
Research & Development i14.61M2.94B
Operating Income (EBIT) i-37.10M8.05B
Operating Margin i-48.0%18.2%
EBITDA i-36.76M12.03B
EBITDA Margin i-47.5%27.1%
Pre-Tax Income i-38.42M8.47B
Pre-Tax Income % of Revenue i-49.7%19.1%
Income Tax i10,0001.94B
Income Tax % of Revenue i0.0%4.4%
Net Income (Profit) i-38.43M6.52B
Profit Margin i-49.7%14.7%

Balance Sheet & Liquidity Metrics

MetricSGHT (2025)ABT (2025)
Cash & Equivalents i91.97M8.52B
Total Current Assets i112.73M26.00B
Total Current Assets % of Revenue i145.7%58.6%
Total Current Liabilities i11.03M16.50B
Total Current Liabilities % of Revenue i14.3%37.2%
Long-Term Debt i40.30M10.83B
Long-Term Debt % of Revenue i52.1%24.4%
Total Shareholders Equity i63.94M52.77B
Retained Earnings i-384.72M49.78B
Retained Earnings % of Revenue i-497.3%112.3%
Property, Plant & Equipment i2.65M17.57B

Cash Flow Statement Comparison

MetricSGHT (2025)ABT (2025)
Operating Cash Flow i-24.47M10.80B
Operating Cash Flow % of Revenue i-31.6%24.4%
Capital Expenditures i-224,000-2.17B
Free Cash Flow i-29.92M7.40B
FCF Margin i-38.7%16.7%
Debt Repayment i0-1.50B
Common Stock Repurchase iN/A-893.00M

Short Interest & Institutional Ownership Analysis

MetricSGHTABT
Shares Short i1.07M23.83M
Short Ratio i2.421.93
Short % of Float i2.70%1.53%
Shares Outstanding i53.49M1.74B
Float Shares i35.29M1.73B
% Held by Insiders i20.96%0.54%
% Held by Institutions i48.49%82.23%
% Held by Public i30.55%17.23%

Dividend Analysis & Yield Comparison: Sight Sciences Inc. vs Abbott Laboratories

MetricSGHTABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026